Table 3.

Response rates in evaluable patients with CLL/SLL in part 2

Best response, n (%) [95% CI]	Treatment-naive, n = 22	Relapsed or refractory, n = 56	Total, N = 78
ORR	22 (100) [84.56-100]	53 (94.6) [85.13-98.88]	75 (96.2) [89.17-99.2]
CR	1 (4.5)	1 (1.8)	2 (2.6)
PR	18 (81.8)	45 (80.4)	63 (80.8)
PR-L	3 (13.6)	7 (12.5)	10 (12.8)
SD	0	2 (3.6)	2 (2.6)
PD	0	0	0
Missing/not evaluable	0	1 (1.8)	1 (1.3)

Sixteen patients were not included because the first protocol-specified response assessment time point of 3 months from treatment start date had not been reached and progression had not been observed.

PD, progressive disease; SD, stable disease.